ConferencePoster
 (2017)

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

Escudier, B; Tannir, NM; McDermott, DF; Frontera, OA; Melichar, B; Plimack, ER; Barthelemy, P; George, S; Neiman, V; Porta, C; Choueiri, TK; Powles, T; Donskov, F; Salman, P; Kollmannsberger, CK